[HTML][HTML] Real-world study of osimertinib in Korean patients with epidermal growth factor receptor T790M mutation–positive non–small cell lung cancer
JH Lee, EY Kim, CK Park, SY Lee, MK Lee… - Cancer Res …, 2023 - synapse.koreamed.org
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
[PDF][PDF] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
JH Lee, EY Kim, CK Park, SY Lee, MK Lee… - Cancer Res …, 2023 - e-sciencecentral.org
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
JH Lee, EY Kim, CK Park, SY Lee… - Cancer Research …, 2023 - cuk.elsevierpure.com
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.
JH Lee, EY Kim, CK Park, SY Lee, MK Lee… - Cancer Research and …, 2022 - europepmc.org
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation-positive non-small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation-positive non-small cell lung cancer, real-world evidence …
[PDF][PDF] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer
JEL Yoon, SH Lee, SJ Kim, SY Lee, JH Lim10… - researchgate.net
Materials and Methods Patients with confirmed EGFR T790M after disease progression of
prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary …
prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary …
[HTML][HTML] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
JH Lee, EY Kim, CK Park, SY Lee, MK Lee… - Cancer Research and …, 2022 - e-crt.org
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
JH Lee, EY Kim, CK Park, SY Lee, SH Yoon… - Cancer Research and … - KoreaMed
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …
[PDF][PDF] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer
JH Lee, EY Kim, CK Park, SY Lee, MK Lee, SH Yoon… - 2023 - ir.ymlib.yonsei.ac.kr
Purpose: Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation-positive non-small cell lung cancer, real-world evidence …
receptor (EGFR) T790M mutation-positive non-small cell lung cancer, real-world evidence …
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
이장호， 김은영， 박철규， 이신엽， 이민기… - Cancer Research and …, 2023 - dbpia.co.kr
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (iEGFR/i) T790M mutation–positive non–small cell lung cancer, real-world …
receptor (iEGFR/i) T790M mutation–positive non–small cell lung cancer, real-world …
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
JH LEE, EY KIM, CK PARK, SY LEE… - Cancer Research …, 2023 - pesquisa.bvsalud.org
Purpose@# Although osimertinib is the standard-of-care treatment of epidermal growth
factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world …
factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world …